All Interventions

    Testosterone Replacement Therapy

    Hormones
    Androgen Therapy

    Restoration of testosterone levels to optimal physiological range in men with hypogonadism or age-related decline.

    Evidence Summary

    9
    / 10Score
    Strong
    Strong RCT Evidence

    The landmark TRAVERSE trial (Lincoff et al., NEJM 2023; 5,246 men aged 45–80 randomized, 5,204 in the full-analysis set, with symptomatic hypogonadism and elevated cardiovascular risk, mean follow-up 33 months) established cardiovascular non-inferiority: major adverse cardiac events occurred in 7.0% of the testosterone group versus 7.3% of placebo (hazard ratio 0.96, 95% CI 0.78–1.17). On the strength of these data, in February 2025 the U.S. FDA removed the long-standing boxed ("black-box") cardiovascular warning from all testosterone products, concluding that testosterone does not increase the risk of major adverse cardiac events when used for documented hypogonadism. Prespecified secondary analyses still showed modestly higher rates of atrial fibrillation (3.5% vs 2.4%, P=0.02), venous thromboembolism, and acute kidney injury in the testosterone group. A dedicated fracture sub-study (Snyder et al., NEJM 2024) unexpectedly found more clinical fractures with testosterone (3.50% vs 2.46%; hazard ratio 1.43, 95% CI 1.04–1.97), so testosterone should not be used to prevent fractures. 2024–2026 systematic reviews and position statements continue to concur: in properly selected, symptomatic hypogonadal men, testosterone therapy has a reassuring cardiovascular profile alongside meaningful benefits for body composition, sexual function, mood, and bone density — provided hematocrit, PSA, blood pressure, and cardiac rhythm are monitored. This is educational information, not medical advice.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Exogenous testosterone binds androgen receptors, restoring anabolic signaling, supporting muscle protein synthesis, bone density, erythropoiesis, and CNS function.

    Who Is This For?

    Symptomatic hypogonadism, documented low testosterone, absence of contraindications. PSA and hematocrit baseline required.

    Protocol & Dosing

    Dose

    Cypionate: 100-200mg/week. Gels: 50-100mg daily. Target total T 700-1000 ng/dL.

    Frequency

    Weekly injections or daily topicals

    Duration

    Ongoing with monitoring

    Protocol Summary

    Various delivery methods: injections (cypionate/enanthate), gels, pellets, patches. Monitoring essential.

    Latest Evidence

    TRAVERSE trial (2023–2024) + 2025 FDA update

    TRAVERSE was a randomized, double-blind, placebo-controlled cardiovascular safety trial of 5,246 men aged 45–80 (5,204 in the full-analysis set) with symptomatic hypogonadism and elevated cardiovascular risk, followed for a mean of ~33 months. Testosterone was non-inferior to placebo for major adverse cardiac events (7.0% vs 7.3%; hazard ratio 0.96, 95% CI 0.78–1.17), resolving a long-standing safety question — and in February 2025 the U.S. FDA removed the long-standing boxed ('black-box') cardiovascular warning from all testosterone products on the strength of these data. Prespecified secondary analyses still showed higher rates of atrial fibrillation (3.5% vs 2.4%), venous thromboembolism, and acute kidney injury with testosterone, and a dedicated fracture sub-study found more clinical fractures with testosterone (3.50% vs 2.46%; hazard ratio 1.43), so it should not be used to prevent fractures.

    These findings apply to men with documented hypogonadism under medical supervision. Testosterone should not be used to prevent fractures. Therapy requires monitoring of hematocrit, PSA, and cardiac rhythm. This is educational information, not medical advice.

    Human RCT Safety Data · TRAVERSE

    Event rates over ~33 months: testosterone vs placebo

    5,246 hypogonadal men aged 45–80 with high cardiovascular risk (5,204 analysed). Testosterone was non-inferior to placebo for major adverse cardiac events (MACE) — the basis for the FDA removing testosterone's cardiovascular black-box warning in February 2025 — but showed modestly higher rates of atrial fibrillation, venous thromboembolism (VTE), and clinical fracture, signals that warrant monitoring. Sources: TRAVERSE, Lincoff et al., NEJM 2023 (NEJMoa2215025); fracture sub-study Snyder et al., NEJM 2024 (NEJMoa2308836).

    Interactions & Precautions

    Contraindications

    • Prostate cancer
    • Breast cancer
    • Polycythemia
    • Untreated sleep apnea
    • Fertility goals (relative)

    Potential Risks

    • •Fertility suppression
    • •Cardiovascular effects (disputed)
    • •Prostate concerns
    • •Dependency

    Potential Side Effects

    Acne
    Polycythemia
    Testicular atrophy
    Gynecomastia (if aromatization)
    Mood changes

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Optimize estradiol management with an aromatase inhibitor only if clinically indicated. Consider HCG to maintain testicular function and fertility. Monitor hematocrit, PSA, blood pressure, and cardiac rhythm regularly. In light of TRAVERSE (NEJM 2023–2024): screen for and monitor atrial fibrillation and venous thromboembolism risk, and do not prescribe testosterone for fracture prevention — the fracture sub-study showed increased fracture incidence. In February 2025 the FDA removed the boxed cardiovascular warning from testosterone products on the basis of TRAVERSE. Reserve therapy for symptomatic, biochemically confirmed hypogonadism.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $$

    Accessibility

    Widely available

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation